# Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

> **NCT04443322** · NA · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Liver Carcinoma
- Liver Transplant; Complications

## Interventions

- **DRUG:** Durvalumab Injection
- **DRUG:** Lenvatinib 4 MG

## Key facts

- **NCT ID:** NCT04443322
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-19
- **Primary completion:** 2021-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443322, "Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04443322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*